Close

New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase

Go back to New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
National Health Partners, Inc. (NYSE: HPR) Delayed: 4.73 --0 (-0%)
Previous Close $4.73    52 Week High $0.28 
Open $3.62    52 Week Low $0.25 
Day High $4.73    P/E N/A 
Day Low $4.73    EPS $-0.23 
Volume 3,248       

HORIZON PHARMA (NASDAQ: HZNP) Delayed: 116.30 --0 (-0%)
Previous Close $116.30    52 Week High $23.44 
Open $116.30    52 Week Low $13.06 
Day High $116.30    P/E N/A 
Day Low $116.30    EPS $-0.96 
Volume 117